Journal of Neuroinformatics and Neuroimaging

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44 7460731551

Rapid Communication - Journal of Neuroinformatics and Neuroimaging (2022) Volume 7, Issue 1

Neuroimaging biomarkers for parkinsonian disorders and its diagnosis.

Joseph Walker*

Department of Neurology, University of Illinois, Champaign, IL, USA

*Corresponding Author:
Joseph Walker
Department of Neurology
University of Illinois, Champaign, IL, USA
E-mail: [email protected]

Received: 25-Jan -2022, Manuscript No. AANN-22-104; Editor assigned: 27-Jan -2022, PreQC No. AANN -22-104(PQ); Reviewed: 14- Feb-2022, QC No. AANN-22-104; Revised: 18- Feb-2022, Manuscript No. AANN-22-104(R); Published: 24-Feb-2022, DOI:10.35841/aann-7.1.104

Citation: Walker J. Neuroimaging biomarkers for parkinsonian disorders and its diagnosis. J NeuroInform Neuroimaging. 2022;7(1):104

Visit for more related articles at Journal of Neuroinformatics and Neuroimaging


Parkinsonian disorders are the most common neurodegenerative diseases after Alzheimer's disease. In about 20% of patients, parkinsonism is not due to Parkinson's disease (PD) pathology, which then is commonly referred to as an atypical parkinsonian disorder (AP). The most frequent forms of underlying neurodegenerative pathologies in AP are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD). Neuronal degeneration is generally much more aggressive and symptomatic therapy is much less effective in these disorders than in PD. This does not only lead to a significantly shorter survival but also to a dramatically steeper loss of function, for example, in activities of daily living. From a neuropathological perspective, parkinsonian disorders are proteinopathies and distinguishable with regard to the form and localization of pathological protein aggregates.


Vestibular, Neurotology, Neurodevelopment.


In PD, alpha-synuclein accumulation in the form of intraneuronal Lewy bodies occurs progressively and probably largely in an ascending order from the brainstem to thecerebral cortex. MSA is also considered an alpha-synucleinopathy, although protein aggregates mostly appear as cytoplasmic oligodendroglial inclusion bodies PSP then again is described by intracerebral total of tau proteins, overwhelmingly including isoforms with four microtubule-restricting locale rehashes (4R-Tau), in neurofibrillary tangles, oligodendrocytic loops, and astrocytic tufts. This pathology by and large happens first in the midbrain and the basal cores and later additionally in the cerebral cortex (ordinarily beginning in the front facing projection). As opposed to PSP, 4R-tau pathology in CBD shows up more as astrocytic plaques than tufted astrocytes however can be found as brain incorporations as well as strings in dark and white matter. Significantly, there is impressive clinical and neuropathological cross-over between the illnesses especially inside subtypes, for example, the parkinsonian (MSA-P) and cerebellar variations of (MSA-C) and between PSP-range tauopathies, like the Richardson's disorder (PSP-RS), parkinsonism-variation (PSP-P), and unadulterated step freezing, among others [1].

Momentum pathophysiological speculations recommend that a focal system of infection movement is the spread of pernicious protein pathologies along useful mind organizations, which opens up the likelihood to hinder this pathogenic course by remedial mediation. To be sure, new atomic treatment techniques focusing on protein conglomerations are prepared for clinical preliminaries and hold the guarantee to significantly work on the visualization of AP. Be that as it may, the ID of possibility for clinical preliminaries is tricky in light of the fact that exact early conclusion of the sort of basic pathology can be incredibly troublesome. A principle justification behind this is a solid jumble between clinical show and neurotic substance and the presence of an assortment of covering conditions. Albeit a few clinical elements exceptionally connect with the hidden obsessive substance, it is progressively perceived that in AP, the clinical element can have restricted cross-over with a neurotic element as well as the other way around.

In aggregate, there is a dire requirement for instruments to assist with the early discovery of neurodegenerative cycles, the early separation of the hidden pathology, and the objective appraisal of infection movement. In this article, we set out a calculated structure intending to describe in more detail the sort of neuroimaging biomarkers required, distinguish the current difficulties in attributing utility of these biomarkers, and propose standards for a framework that might direct future examinations to conquer these difficulties [2].

There is plenty of evidence for a relatively large mismatch between clinical and pathological disease entities. While in some cases the clinical syndrome is highly indicative of the underlying pathology (e.g., clinical PSP-Richardson syndrome with 4R-neuroglial pathology), predicting a pathological entity based only on the clinical presentation of the patient is highly problematic in most cases, particularly during the early clinical stage of the disease. In the relatively large cohort of Lee and colleagues, only 35% of patients with corticobasal syndrome actually had CBD as a pathological substrate, while 23% had AD pathology and 13% had PSP pathology. Conversely, the same pathological entity can be associated with a large variety of different syndromes. In their seminal paper, Williams and Lees have described various syndromes and variants of presentations that can be associated with PSP pathology. Considering that the large mismatch between neuropathology and clinical presentation has translated to suboptimal diagnostic accuracy of parkinsonian syndromes, it currently makes sense to differentiate diagnostic properties of biomarkers according to these categories [3].

The ultimate goal of a therapeutic intervention is to stop and reverse disease progression, or at least to slow it down. It is increasingly clear that the neurodegenerative cascade can start many years, or even decades, before first clinical symptoms. Therefore, a therapeutic intervention targeting protein aggregation could be more effective, the earlier it is started. However, diagnostic accuracy for clinical entities and even more so for pathological entities is generally low when only few or prodromal symptoms are detectable by the clinician. Neuroimaging biomarkers may help increasing diagnostic accuracy in this phase. For an unambiguous definition of what constitutes a diagnostic biomarker, the FDA-NIH Biomarker Working Group has published a compendium of definitions a diagnostic biomarker is “used to detect or confirm presence of a disease or condition of interest or to identify individuals with a subtype of the disease [4].

Importantly, the performance of a diagnostic biomarker has to be tested under defined conditions of use. The biomarker can only be put to use for patient selection in clinical trials, if the validity on the individual level in the intention-to-test population (the kind of group to which the diagnostic test will be applied to) is known. For example, a biomarker that distinguishes PSP patients from healthy controls may not be applicable in a scenario, where the intention-to-test population is composed of patients with PSP, but also other forms of parkinsonism. In addition, although it may be helpful to explore the potential of neuroimaging biomarkers in convenience samples (i.e., ad hoc clinic cohorts), one cannot properly infer the performance of the diagnostic biomarker in studies using other sampling settings. Moreover, the time point and clinical certainty at which the test is applied should reflect the intended-use scenario. If a diagnostic biomarker performs well in patients who already have a clinical diagnosis with a fully developed syndrome, this does not mean that it will perform well in patients at the very early stage and with prodromal symptoms or other clinical variants. It is self-evident that the performance of a diagnostic neuroimaging biomarker should be assessed in a way that is statistically meaningful to be applicable in clinical trials [5].


  1. Elbaz A, Carcaillon L, Kab S. Epidemiology of Parkinson's disease. Revue Neurologique. 2016;172(1):14-26.
  2. Indexed at, Google Scholar, Cross Ref

  3. Horvath J, Burkhard PR, Bouras C, et al. Etiologies of P arkinsonism in a Century‐Long Autopsy‐Based Cohort. Brain Pathol. 2013;23(1):28-33.
  4. Indexed at, Google Scholar, Cross Ref

  5. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: A review of the literature. Mov Disord. 2007;22(15):2141-48.
  6. Indexed at, Google Scholar, Cross Ref

  7. O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(5):1362-72.
  8. Indexed at, Google Scholar, Cross Ref

  9. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.
  10. Indexed at, Google Scholar, Cross Ref

Get the App